Pyxis Oncology (PYXS) Receivables - Other (2022 - 2023)
Pyxis Oncology (PYXS) posted quarterly Receivables - Other of $21000.0 for Q4 2023, down 96.49% year-over-year from $598000.0 in Q4 2022, and down 96.49% quarter-over-quarter from $598000.0 in Q4 2022.
Pyxis Oncology (PYXS) Receivables - Other (2022 - 2023) Analysis & Trends
Pyxis Oncology (PYXS) has reported Receivables - Other for 2 consecutive years, with $21000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Receivables - Other fell 96.49% year-over-year to $21000.0; the TTM figure through Dec 2023 stood at $21000.0 (down 96.49% YoY), while the FY2023 annual figure was $21000.0, down 96.49% from the prior year.
- Receivables - Other fell to $21000.0 in Q4 2023 per PYXS's latest filing, from $598000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $598000.0 in Q4 2022 and bottomed at $21000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Pyxis Oncology | 201.57 Mn | 168.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2022 | 598,000.00 |
| Dec 31, 2022 | 598,000.00 |